Call for Abstract

International Conference on Neurocognitive Disorders, will be organized around the theme “Breakthroughs and Achievements in Neurocognitive Research”

Neurocognitive Disorders 2016 is comprised of 8 tracks and 0 sessions designed to offer comprehensive sessions that address current issues in Neurocognitive Disorders 2016 .

Submit your abstract to any of the mentioned tracks. All related abstracts are accepted.

Register now for the conference by choosing an appropriate package suitable to you.

Neurodegenerative disorders are defined by the progressive decline of neuronal functions in a spatiotemporal fashion, which leads to intensifying neurological symptoms, in some cases, with devastating speed. This is accompanied by the steady intensity of neuropathological findings from more to less affected regions in the nervous system. The molecular pathway driving constant decline of disease symptoms and pathology is not yet understood. However, the enlargement of pathological protein assemblies, spreading from cell-to-cell, may well explain these phenomena.

We will bring neurologists and   neuropathologists basic scientists from a wide variety of neurodegenerative diseases to discuss the conclusion of these mechanisms for building disease models and therapeutic strategies. We will also speak about the similarities and differences between the different classes of neurodegeneration, comparing to prototypical prion diseases.

Neurocognitive disorders include delirium, mild cognitive impairment and dementia which are characterized by decline from an attained level of cognitive functioning. The disorders have diverse clinical characteristics and aetiologies, with Alzheimer disease, frontotemporal degeneration, cerebrovascular disease, Lewy body disease, traumatic brain injury, infections, and alcohol abuse showing common causes. 

A neurocognitive deficit is a reduction or impairment of cognitive function, but mainly when physical changes can be seen to have occurred in brain, such as after neurological and mental illness, drug use, or brain injury.

Clinical neuropsychologist use neuropsychological tests to detect and understand such deficits and may be involved in the rehabilitation of an affected person. This discipline that studies neurocognitive deficits to infer normal psychological function is known as cognitive neuropsychology.

Neurovascular disorders affect the cerebral vascular system and the spinal cord that encompasses any abnormality of the blood vessels supplying the brain and spine. Abnormalities may be narrowing of arteries which reduce blood flow to the brain that tends to risk of Stroke and weakening of arteries that leads brain aneurysms and increase the risk of intracranial bleeding. Very common Neurovascular Diseases are brain aneurysms, stroke, arteriovenous malformations, spinal vascular malformations, carotid stenosis, cerebral hemorrhage,   intracranial atherosclerosis, Vasculitis etc. 

Usually, people having a stroke will be having the sudden onset of weakness or numbness on one side of their body. They may also have difficulty in seeing or speaking, or feel a loss of balance or coordination. Sometimes people will have only mild symptoms that will totally resolve. For example, they may feel weak or clumsy in one hand, but then it goes away several minutes later. They may suddenly lose vision in one eye, but after a short time it completely returns to normal. They may ignore it but it’s a warning sign. That’s a transient ischemic attack, and it’s a caution that they are at risk for a large stroke in the future.

This session includes Diagnostic Neuropsychology and Neuroimaging, HIV-Associated Neurocognitive Disorders, Frontotemporal dementia etc.

Traumatic brain injury takes place when an external mechanical force causes brain dysfunction. Traumatic brain injury usually the results from a violent blow or jolt to the head or body. An object penetrating the skull, such as a bullet or shattered piece of skull, also can cause traumatic brain injury.

We will be addressing Neurogenesis of brain development, Cerebral metabolic dysfunction, Paralysis, Aging and Neurodegeneration, Brain research , Anti-amyloid therapy  in this particular session

 

Alzheimer’s is very common cause of dementia among older adults. Dementia is the loss of cognitive functioning—thinking, reasoning, remembering, and behavioral abilities to such an extent that it interferes with a person’s daily life activities. Dementia also ranges in severity from the mildest stage, when it is just beginning to affect a person’s functioning, to the last stage, when the person must depend completely on others for basic activities of daily living.

The causes of dementia can vary, depending on the types of brain changes that may be taking place. Other dementias include Lewy body dementia, vascular dementia, and also frontotemporal disorders. It is common for people to have mixed dementia—a combination of more disorders, at least one of which is dementia. For example, some people have both Alzheimer's disease and vascular dementia.

It also includes Alcohol addiction and mental health, Metabolic syndrome and Alzheimer’s disease, Drug treatment and therapies

There is substantial clinical need to recognize the individuals who need care for cognitive issues that go beyond normal aging. These problems are noticeable, but clinicians have lacked a reliable diagnosis by which to assess symptoms the most proper treatment or services. Recent studies suggest that identifying mild neurocognitive disorders in the early stages itself may allow interventions to be more effective. Early intervention efforts may enable the use of treatments that are ineffective at more severe levels of impairment and may prevent or slow progression. Researchers will analyze how well the new diagnostic criteria address the symptoms, as well as potential therapies like educational or brain stimulation.

Major neurocognitive disorder was previously known as dementia and the primary feature of all neurocognitive disorders is an acquired cognitive decline in one or more cognitive domains. Neurocognitive disorders can affect memory, concentration, Knowledge, language, perception, and social cognition.

 

Neuro-pharmaceutics focuses on discovery of therapeutic targets, and then translating those discoveries into drug and therapy development. Neuropharmaceutics is the largest potential growth sector of the pharmaceutical industry. However, this growth is blocked by the problem of the blood-brain barrier